Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. - Wikidata - wikimedia - TriplyDB

Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons.

Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons.

http://www.wikidata.org/entity/Q33541763

about

Vaccines for preventing influenza in healthy adults Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults Prevention and treatment of influenza with hyperimmune bovine colostrum antibody Efficacy and correlates of protection for cell culture-derived and egg-derived inactivated influenza vaccines in younger adults.Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009.Immunogenicity of trivalent inactivated influenza vaccination received during pregnancy or postpartum Antibodies against conserved antigens provide opportunities for reform in influenza vaccine design Safety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: results of a randomized trial Phase IV: randomized controlled trial to evaluate lot consistency of trivalent split influenza vaccines in healthy adults Incidence of influenza in healthy adults and healthcare workers: a systematic review and meta-analysis.CD154 expression is associated with neutralizing antibody titer levels postinfluenza vaccination in stem cell transplant patients and healthy adults Influenza vaccine immunogenicity in patients with primary central nervous system malignancy.Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis Age-related changes in durability and function of vaccine-elicited influenza-specific CD4(+) T-cell responses.A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza Disease Strategies to increase influenza vaccination rates: outcomes of a nationwide cross-sectional survey of UK general practice.Vaccine-associated reduction in symptom severity among patients with influenza A/H3N2 disease.Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains.CD4 T cell help is limiting and selective during the primary B cell response to influenza virus infection.Influvac, a trivalent inactivated subunit influenza vaccine.Assessing vaccine efficacy in influenza clinical trials: challenges and difficulties.Pilot investigation into the sickness response to influenza vaccination in adults: Effect of depression and anxiety.Evidence update: GlaxoSmithKline's inactivated quadrivalent influenza vaccines.Safety of a Trivalent Inactivated Influenza Vaccine in Health Care Workers in Kurdistan Province, Western Iran; A Longitudinal Follow-up Study.Recent advances in the production of recombinant subunit vaccines in Pichia pastoris.Increasing herd immunity with influenza revaccination.Rapid changes in serum cytokines and chemokines in response to inactivated influenza vaccination.Log transformation: application and interpretation in biomedical research.The seasonal incidence of symptomatic influenza in the United States.A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season.Magnitude of potential biases in a simulated case-control study of the effectiveness of influenza vaccination.No evidence for the immunocompetence handicap hypothesis in male humans.A Novel Representation of Vaccine Efficacy Trial Datasets for Use in Computer Simulation of Vaccination Policy.Prospective cohort studies to evaluate the safety and immunogenicity of the 2013, 2014, and 2015 seasonal influenza vaccines produced by Instituto Butantan The Accuracy of Influenza Diagnosis Estimating Vaccine-Driven Selection in Seasonal Influenza Reply: Cochrane rearranged

P2860

Q24197955-F467F4F6-DFA2-46AA-B8E2-4E48D453E811 Q24614487-87A0CFAC-2B25-4CE8-8D1E-23C098F4AEB1 Q24622008-24E8F5CC-31D7-459C-8030-7E3367BFE3C4 Q28748705-20593095-E86C-45CF-9E01-683C17278243 Q30226435-17AF49FF-8D58-4E12-9A12-D017FD81A056 Q30399334-32B97B64-2A5D-4123-934B-5DDFE82EA3D1 Q30413366-BE93A362-EF9B-4ACC-84A6-95C2E5A15DE1 Q30416502-DECFEA20-0660-46DA-B481-0728CB06A1AD Q30429170-DAEBCF0C-A56B-4DFD-B58D-42CBE1C0F00C Q33723445-A8F38D27-CB26-4524-8B57-80A968FC1A8A Q34058480-64A7EB4E-7C34-4CD1-ABBE-2DFA9351FFEF Q34104346-ACDAE9F6-9532-40E5-8BD5-99C16C6BCCBF Q34511678-F764055B-A600-4887-9096-2731EA570012 Q34729188-2933B92B-694B-4D7E-9016-D059BDF2A1B1 Q34783486-9D893C87-1655-479A-8B5D-48B224CCB6D7 Q35575511-0DAA25F8-99F6-4C59-94FA-CAD973B4B0E5 Q35815281-DC22D259-C340-4262-AF93-99444C95DFCA Q35837747-D15A11F4-C939-4190-B79B-209DEFB7C17D Q35981831-0CEC2006-87C6-4D61-A407-4D928C1AAB91 Q36385284-CA209978-FCF1-419D-98FF-E07F7AB109C2 Q36854011-6802B55C-EB9F-4B09-B43B-087FADEB2F92 Q37547668-FBD797BE-3384-4A6B-8398-77F6648E5C66 Q37812615-B752068F-23A1-4BB5-AA21-EBBEDF631AF3 Q38127468-BFBDF490-6EAC-4CD7-A3F7-6BBDB2A4CC0E Q38639288-4ABA6A98-DCF6-4E8C-94BB-6B2ABD43CA20 Q38660898-3E2EB2E9-85F8-4445-8903-D42403D2B791 Q38846084-CBB77A82-50C1-4211-A7EC-767504604706 Q38849581-0959B936-7A42-4282-97F2-4C2FA6E8D8B6 Q41201663-03933A8E-7216-4125-82E4-C5900334A7E0 Q41921639-DD26A5D7-8A54-4D99-8C01-2D7B7197F9AB Q46104233-882BE37F-D696-41E3-8700-723351393B87 Q47690334-C489A2B4-8044-4588-8654-4593458AFB15 Q47843797-D6FD1439-F69B-4D31-9108-9EB85AE75EB9 Q53091538-35F5E7C9-6A35-42C2-BBAE-73F05A1BADE4 Q55033958-301569AD-EEEC-4ECA-BC0E-680C29638398 Q55052340-075C67FF-32E8-411C-A7E1-6A58FB72779D Q56525461-48408E7C-18E8-47B5-9405-83BA5EEE37F0 Q57279195-56724E52-0567-43E6-BB6A-8D86EBE3C454 Q58722425-7F5FEDB3-3301-400C-A28D-EDEDF576FF52 Q84819137-0896defd-43fb-4284-4943-a6bd1259bd1c

P2860

Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons.

http://www.wikidata.org/entity/Q33541763

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Safety, efficacy, and immunoge ...... al over two influenza seasons.

@ast

Safety, efficacy, and immunoge ...... al over two influenza seasons.

@en

Safety, efficacy, and immunoge ...... al over two influenza seasons.

@nl

type

label

Safety, efficacy, and immunoge ...... al over two influenza seasons.

@ast

Safety, efficacy, and immunoge ...... al over two influenza seasons.

@en

Safety, efficacy, and immunoge ...... al over two influenza seasons.

@nl

prefLabel

Safety, efficacy, and immunoge ...... al over two influenza seasons.

@ast

Safety, efficacy, and immunoge ...... al over two influenza seasons.

@en

Safety, efficacy, and immunoge ...... al over two influenza seasons.

@nl

P1433

Q33541763-1DE1E186-0EC1-4174-A554-CE32AEB127A0

P1476

Q33541763-DC39C6F5-48B4-4F59-984D-72D2692B0DAC

P2093

Q33541763-10624BD4-4525-48A4-BB7E-93A25FF438D7

Q33541763-8886A699-932F-4B64-85C6-AC1E13B5F34F

Q33541763-8BBA45BA-3395-42B9-9CFC-C9E24A0C46F3

Q33541763-D7FF32A6-9FDC-4CDB-9A8D-AF620258F9E0

Q33541763-DA623A8C-F2B3-456F-8672-4898E85CFDA6

Q33541763-DE85B46F-2F09-4B4D-9D69-712554AE2EE4

P2860

Q33541763-076249A5-3D1D-4B0D-8A60-5434327EE066

Q33541763-108D3505-EAB5-490D-88FF-EE5DE871C9F7

Q33541763-11363D64-C27F-4A92-9B22-DB769E06671B

Q33541763-24B76048-B9D1-402D-903B-43A5AB6C855A

Q33541763-2E78505B-B0AF-46A9-AB92-06D3F9430489

Q33541763-3628B7B5-4A58-448C-9BA9-F8A71F343DC1

Q33541763-38ABF91E-138A-463F-B591-FC0F3ADC4D8C

Q33541763-48066D9D-D6CC-40C2-8C8A-80F3E5A9E639

Q33541763-4CAA8139-6B01-4205-8CFE-7E630BECA354

Q33541763-6620EA25-F607-4263-9F20-83AE0CC9AB6D

P2888

Q33541763-75B95D36-30BE-4085-8746-F7DF04B86CF3

P304

Q33541763-FE478D48-D64E-4CCF-837E-DCE56958749B

P31

Q33541763-82686036-5F07-4BF4-8B88-E92A3974D463

P356

Q33541763-EC15F34B-FF41-4F8D-9145-635EC7D8B725

P478

Q33541763-D0B92D45-2C31-437E-89D3-DBFA932F90CA

P50

Q33541763-0A201E2E-710B-472A-905F-EA367D5525DF

P577

Q33541763-B7A11FBC-FDF4-4192-BA7B-9D7297F6F735

P5875

Q33541763-4C401375-940C-4518-A51C-871049F93AF8

P6179

Q33541763-DEFD02E8-DACA-4883-9E6C-5521FA20B4B4

P698

Q33541763-F87C083C-6DFA-4FD4-9C44-DD5B072C7C7D

P921

Q33541763-C2683CA6-B1B4-4F21-93E5-D9611D1F0749

P932

Q33541763-FDA27AB1-5514-4B40-8508-E34F1FD2EC51

P356

1471-2334-10-71

P1433

BMC Infectious Diseases

P1476

Safety, efficacy, and immunoge ...... al over two influenza seasons.

@en

P2093

John Balser

http://www.w3.org/2001/XMLSchema#string

John J Treanor

http://www.w3.org/2001/XMLSchema#string

Lisa A Jackson

http://www.w3.org/2001/XMLSchema#string

Louis Fries

http://www.w3.org/2001/XMLSchema#string

Manjusha J Gaglani

http://www.w3.org/2001/XMLSchema#string

Nancy Bouveret

http://www.w3.org/2001/XMLSchema#string

P2860

Vaccines for preventing influenza in healthy children

Vaccines for preventing influenza in healthy adults

The annual impact of seasonal influenza in the US: Measuring disease burden and costs

Mortality associated with influenza and respiratory syncytial virus in the United States

Influenza-associated hospitalizations in the United States

Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease.

Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example

Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses.

Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007.

Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination.

P2888

1471-2334-10-71

P304

71

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2334-10-71

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Harry L Keyserling

P577

2010-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42254610

http://www.w3.org/2001/XMLSchema#string

P6179

1047163670

http://www.w3.org/2001/XMLSchema#string

P698

20236548

http://www.w3.org/2001/XMLSchema#string

P921

P932

2845585

http://www.w3.org/2001/XMLSchema#string